Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort

Background:  Individuals with severe atopic asthma are poorly controlled with standard treatments, including corticosteroids. A humanized monoclonal antibody binding immunoglobulin E (IgE), omalizumab, is approved to treat patients that are managed poorly despite optimal therapy and that have elev...

Full description

Bibliographic Details
Main Authors: David Haile-Meskale, Ron Olivenstein, Toby Mcgovern, Cathy Fugere, James G. Martin
Format: Article
Language:English
Published: McGill University 2020-07-01
Series:McGill Journal of Medicine
Subjects:
Online Access:https://mjm.mcgill.ca/article/view/75